PUBLIC COMPANY
save$GNLXGENELUX Corp
$GNLXWestlake Village, CA, USupdated 13d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- phase2Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- phase2A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
- phase1Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
- —Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 25, 26SELLSmalling Ralph· Head of Regulatory−$602↗
- Mar 24, 26SELLZindrick Thomas· President and CEO−$9K↗
- Mar 24, 26SELLCappello Joseph· Chief Technical Officer−$2K↗
- Mar 24, 26SELLYu Yong· SVP, Clinical Development−$2K↗
- Mar 24, 26SELLSmalling Ralph· Head of Regulatory−$835↗
- Mar 2, 26SELLThomas John· −$29K↗
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that